Suppr超能文献

三级护理医院中新冠病毒检测呈阳性患者接种国药疫苗的有效性。

Effectiveness of vaccination (Sinopharm) among Covid-19 positive patients in a tertiary care hospital.

作者信息

Nadeem M, Arshad N, Aurang Zeb M, Mushtaq S, Siddiq S, Zeb J

机构信息

Department of Medicine, Shaikh Khalifa Bin Zayed Al Nahyan/CMH Teaching Hospital (Poonch Medical College), Rawalakot, Pakistan.

Department of Rehabilitation Sciences, Islamabad Medical and Dental College, Islamabad, Pakistan.

出版信息

Arch Razi Inst. 2024 Oct 31;79(5):967-972. doi: 10.32592/ARI.2024.79.5.967. eCollection 2024 Oct.

Abstract

The SARS-CoV-2, has caused a pandemic of acute respiratory disease, 'coronavirus disease 2019' (Covid-19), posed a major threat to health and the international economy during past few years. It is believed that vaccine can stop the rapid spread of the disease. The aim of this study was to evaluate the effect of the Sinopharm vaccine in terms of mortality and severity of the disease among Covid-19 positive patients. This observational cross-sectional study was done at the Department of Medicine and Department of Pathology Shaikh Khalifa Bin Zayed Al-Nahyan/CMH Teaching Hospital (Poonch Medical College), Rawalakot AJK Pakistan from July 2021 to September 2021. Total 350 individuals with greater than or equal to 18 years of age, who were tested positive for Covid-19, were included. Patients who had received two doses of the vaccine at least 28 days apart were considered as vaccinated. The Sinopharm vaccination status was checked among patients. The severity of Covid-19 was categorized as mild, moderate and severe. A log rank regression test was applied to determine significant difference in disease severity and survival rate. The patients age range was 25-60 years (the patients mean age was 55 years). The majority of participants, 69.1% (n=242), were vaccinated by Sinopharm, and 30.9% (n=108) were non-vaccinated. Most patients had mild disease 80% (n=280) followed by moderate disease 9.7% (n=34), and severe disease 6.6% (n=23), and stratification analysis had significant (p ≤ 0.05) association between vaccinated individuals and disease severity. The overall mortality rate was 3.7%. The mortality rate was 8% (n=9) in none vaccinated individuals, whereas 1.65% (n=4) in vaccinated individuals. The Sinopharm vaccine after both doses was found effective in reducing mortality and disease severity by 98.3% and 94.4%. The study concluded that Sinopharm vaccine after two doses at least 28 days apart given to patients, after two weeks of vaccination is highly effective in reducing the mortality, disease severity and hospital admission in Covid-19 positive patients.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了一场急性呼吸道疾病的大流行,即“2019冠状病毒病”(Covid-19),在过去几年对健康和国际经济构成了重大威胁。人们认为疫苗可以阻止该疾病的快速传播。本研究的目的是评估国药疫苗在Covid-19阳性患者中的死亡率和疾病严重程度方面的效果。这项观察性横断面研究于2021年7月至2021年9月在巴基斯坦阿扎德克什米尔拉瓦拉科特的谢赫·哈利法·本·扎耶德·阿勒纳哈扬/CMH教学医院(蓬奇医学院)医学部和病理学部进行。总共纳入了350名年龄大于或等于18岁且Covid-19检测呈阳性的个体。至少间隔28天接种两剂疫苗的患者被视为接种过疫苗。在患者中检查了国药疫苗接种状况。Covid-19的严重程度分为轻度、中度和重度。应用对数秩回归检验来确定疾病严重程度和生存率的显著差异。患者年龄范围为25至60岁(患者平均年龄为55岁)。大多数参与者,即69.1%(n = 242),接种了国药疫苗,30.9%(n = 108)未接种。大多数患者患有轻度疾病80%(n = 280),其次是中度疾病9.7%(n = 34),重度疾病6.6%(n = 23),分层分析显示接种个体与疾病严重程度之间存在显著(p≤0.05)关联。总体死亡率为3.7%。未接种个体的死亡率为8%(n = 9),而接种个体为1.65%(n = 4)。发现两剂国药疫苗在降低死亡率和疾病严重程度方面分别有效98.3%和94.4%。该研究得出结论,在患者接种疫苗两周后,至少间隔28天接种两剂国药疫苗在降低Covid-19阳性患者的死亡率、疾病严重程度和住院率方面非常有效。

相似文献

1
Effectiveness of vaccination (Sinopharm) among Covid-19 positive patients in a tertiary care hospital.
Arch Razi Inst. 2024 Oct 31;79(5):967-972. doi: 10.32592/ARI.2024.79.5.967. eCollection 2024 Oct.
2
Effect of Vaccination on COVID-19 Severity and Outcome: A Comparative Study in a Tertiary Care Hospital.
J Assoc Physicians India. 2023 Dec;71(12):14-16. doi: 10.59556/japi.71.0403.
5
Severity of SARS-CoV-2 infection among vaccinated individuals: A hospital-based study.
Ceylon Med J. 2022 Dec 31;67(4):143-150. doi: 10.4038/cmj.v67i4.9742.
6
Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report.
Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022026. doi: 10.4084/MJHID.2022.026. eCollection 2022.
7
Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan.
Front Public Health. 2022 Sep 21;10:1008521. doi: 10.3389/fpubh.2022.1008521. eCollection 2022.

本文引用的文献

1
Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.
Postgrad Med J. 2023 Jun 8;99(1171):463-469. doi: 10.1136/postgradmedj-2022-141649.
3
Prediction of Covid-19 infection severity using ABO blood group types and Rh factor.
Pak J Med Sci. 2022 Sep-Oct;38(7):1870-1876. doi: 10.12669/pjms.38.7.5128.
5
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
BMC Public Health. 2022 Aug 20;22(1):1584. doi: 10.1186/s12889-022-14016-9.
6
The Cost of Ignoring Vaccines.
Yale J Biol Med. 2022 Jun 30;95(2):265-269. eCollection 2022 Jun.
8
Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.
N Engl J Med. 2022 Mar 24;386(12):1176-1179. doi: 10.1056/NEJMe2202547. Epub 2022 Feb 23.
10
Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic.
Int J Biol Macromol. 2022 Apr 15;204:161-168. doi: 10.1016/j.ijbiomac.2022.01.118. Epub 2022 Jan 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验